Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
117.84
-0.75 (-0.63%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
72
73
Next >
Forget Nvidia: Billionaires Are Dumping It and Piling Into These 3 Surprising Value Stocks Instead
July 16, 2024
Nvidia's three most-prominent billionaire sellers opted to put their respective fund's capital to work in a trio of brand-name companies trading at a discount.
Via
The Motley Fool
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
July 15, 2024
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
Merck's Acquisition of EyeBio Finalized
July 12, 2024
Merk announced the acquisition of EyeBio, introducing a novel candidate to the company's pipeline, Restoret.
Via
Benzinga
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
July 12, 2024
Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck cancer...
Via
Benzinga
3 Under-$10 Biotech Stocks That Could Make You Rich
July 11, 2024
Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis.
Via
InvestorPlace
Beyond The Numbers: 6 Analysts Discuss Merck & Co Stock
July 11, 2024
Via
Benzinga
Merck & Co Unusual Options Activity
July 05, 2024
Via
Benzinga
Insights Into Merck & Co's Performance Versus Peers In Pharmaceuticals Sector
July 02, 2024
Via
Benzinga
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
July 10, 2024
These are the healthcare stocks to buy as they represent companies with good fundamentals, stable growth visibility and cash flow upside.
Via
InvestorPlace
S&P 500 2024 Q2 Earnings Preview: Aggregate Earnings Reaching A New High Watermark?
July 10, 2024
Q2 estimates have been stable heading into earnings season, potentially setting a lower bar for corporations to beat analyst expectations and surprise to the upside.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Merk Animal Health Completes Acquisition of Elanco Animal Health Assets
July 09, 2024
Merck Animal Health announced the purchase of Elanco Animal Health's aquaculture business.Merck & Company (NYSE:MRK) completed the acquisition of the aquaculture bus
Via
Benzinga
3 Undervalued Blue-Chip Stocks Ready for a Big Comeback
July 09, 2024
Uncover top picks in undervalued blue-chip stocks, unfairly punished yet consistently delivering strong operational results
Via
InvestorPlace
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
July 08, 2024
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health.
Via
Talk Markets
Market Whales and Their Recent Bets on MRK Options
July 01, 2024
Via
Benzinga
A Closer Look at Merck & Co's Options Market Dynamics
June 27, 2024
Via
Benzinga
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
July 07, 2024
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs.
Via
Benzinga
Topics
ETFs
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
July 05, 2024
Roche's SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy did not meet primary endpoints for progression-free survival and overall survival in advanced non-squamous non-small cell lung...
Via
Benzinga
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
July 05, 2024
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.
Via
Investor's Business Daily
Beat the CPI: 7 Blue-Chip Stocks Growing Faster Than Inflation
July 04, 2024
These are the blue-chip stocks to buy as they represent fundamentally strong companies with robust free cash flow visibility
Via
InvestorPlace
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
July 02, 2024
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens...
Via
Benzinga
Exposures
COVID-19
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
July 01, 2024
Ten of the Dow Jones Industrial Average stocks were up double digit percentage in the first half of 2024. A look at the best and worst performers.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going On With Merck Stock On Monday?
July 01, 2024
Merck secures exclusive global rights to develop and commercialize opevesostat (MK-5684/ODM-208) for hormone-dependent cancers. Orion is eligible for milestone payments up to $1.63 billion and tiered...
Via
Benzinga
3 Sectors That Could Get Slammed by Attempts to Reduce U.S. Debt
June 29, 2024
With Washington likely having to take steps to cut the U.S. deficit within the next few years, here are three sectors at risk.
Via
InvestorPlace
7 Quiet Blue-Chip Stocks on the Verge of a Big Breakout Rally
June 28, 2024
These are the undervalued blue-chip stocks to buy as they represent companies with a steady growth and robust cash flow outlook.
Via
InvestorPlace
What's Going On With Merck Stock On Friday?
June 28, 2024
The CDC's Advisory Committee on Immunization Practices recommends Merck's Capvaxive for adults 65+ and certain at-risk individuals 19-64. Merck also announces CHMP's positive recommendation for...
Via
Benzinga
Dow Jones Powerhouse Merck Dives On Surprise FDA Rejection
June 27, 2024
The FDA rejected Merck's Daiichi Sankyo-partnered antibody drug conjugate.
Via
Investor's Business Daily
Topics
Stocks
Exposures
Product Safety
US Equities
This Recent FDA Approval Is Bad News for Pfizer
June 27, 2024
One of the pharma giant's top-selling products is about to face some intense competition.
Via
The Motley Fool
Exposures
Product Safety
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
June 27, 2024
The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The...
Via
Benzinga
Exposures
Product Safety
These Are The Best Dow Jones Stocks Of 2024 Thus Far
June 27, 2024
The AI boom helped to produce two best Dow Jones stocks, including newbie Amazon.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
June 26, 2024
On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threatens to undermine confidence the research abilities of the Darmstadt,...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
72
73
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.